Gregory L. Braden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gregory L. Braden has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Jeffrey G. Mulhern
Department of Medicine and Renal Division, Baystate Medical Center, Springfield, MA and Tufts University School of Medicine, Boston, MA, USA
2 shared publicationsMichael H. O'Shea
Department of Medicine and Renal Division, Baystate Medical Center, Springfield, MA and Tufts University School of Medicine, Boston, MA, USA
2 shared publicationsMichael J. Germain
Department of Medicine and Renal Division, Baystate Medical Center, Springfield, MA and Tufts University School of Medicine, Boston, MA, USA
2 shared publicationsAngelo A. Ucci
Departments of Medicine and Pathology, Baystate Medical Center, Springfield, MA; Department of Pathology, New England Medical Center; and Tufts University School of Medicine, Boston, MA
1 shared publicationBipinchandra Mistry
Department of Medicine, Baystate Medical Center, Springfield, MA, USA
1 shared publicationPaul C. Hetzel
Department of Medicine, Baystate Medical Center, Springfield, MA, USA
1 shared publication
Latest Publications
- 1 October 2004
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 44 (4) , e50-e58
The role of circulating immune complexes and biocompatibility of staphylococcal protein A immunoadsorption in mitomycin C-induced hemolytic uremic syndrome
- 1 October 2004
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 44 (4) , e50-e58
The role of circulating immune complexes and biocompatibility of staphylococcal protein A immunoadsorption in mitomycin C-induced hemolytic uremic syndrome
- Open Access
- 19 February 2004
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 19 (5) , 1149-1153
Acute renal failure and hyperkalaemia associated with cyclooxygenase-2 inhibitors
Background. The renal effects of cyclooxygenase-2 (COX-2) inhibitors have been incompletely elucidated, and acute renal failure (ARF) due to COX-2 inhibitors has been reported. Methods. In order to determine the causes of ARF and hyperkalaemia in five patients during COX-2 inhibitor therapy, we carefully analysed case studies of consecutive in-patients or out-patients referred to our Renal Division over a 6-month period for ARF and hyperkalaemia who had recently received COX-2 inhibitors. Results. ARF developed 2–3 weeks after COX-2 inhibitor therapy in five patients. The ARF was consistent with pre-renal azotaemia from renal hypoperfusion. Four patients were receiving the loop diuretic, furosemide. Four patients developed hyperkalaemia and decreased serum bicarbonate despite diuretic therapy, and one patient had changes in plasma renin activity and aldosterone levels consistent with reversible hyporeninaemic hypoaldosteronism. Renal failure was reversible after discontinuation of diuretics and COX-2 inhibitors. Conclusions. COX-2 inhibitors may cause reversible ARF and hyperkalaemia in patients with oedematous conditions treated with low sodium diets and loop diuretics.
- 19 February 2004
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 19 (5) , 1149-1153
Open AccessAcute renal failure and hyperkalaemia associated with cyclooxygenase-2 inhibitors
Background. The renal effects of cyclooxygenase-2 (COX-2) inhibitors have been incompletely elucidated, and acute renal failure (ARF) due to COX-2 inhibitors has been reported. Methods. In order to determine the causes of ARF and hyperkalaemia in five patients during COX-2 inhibitor therapy, we carefully analysed case studies of consecutive in-patients or out-patients referred to our Renal Division over a 6-month period for ARF and hyperkalaemia who had recently received COX-2 inhibitors. Results. ARF developed 2–3 weeks after COX-2 inhibitor therapy in five patients. The ARF was consistent with pre-renal azotaemia from renal hypoperfusion. Four patients were receiving the loop diuretic, furosemide. Four patients developed hyperkalaemia and decreased serum bicarbonate despite diuretic therapy, and one patient had changes in plasma renin activity and aldosterone levels consistent with reversible hyporeninaemic hypoaldosteronism. Renal failure was reversible after discontinuation of diuretics and COX-2 inhibitors. Conclusions. COX-2 inhibitors may cause reversible ARF and hyperkalaemia in patients with oedematous conditions treated with low sodium diets and loop diuretics.
- 1 May 2000
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 35 (5) , 878-883
Changing incidence of glomerular diseases in adults
- 1 May 2000
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 35 (5) , 878-883
Changing incidence of glomerular diseases in adults